Center for HIV/AIDS Vaccine Immunology (CHAVI)

The summary for the Center for HIV/AIDS Vaccine Immunology (CHAVI) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Center for HIV/AIDS Vaccine Immunology (CHAVI): NIAID seeks to establish a Center for HIV/AIDS Vaccine Immunology (CHAVI) that will support intensive and highly collaborative projects addressing key immunological roadblocks to the discovery and development of a safe and effective HIV vaccine as defined by NIAID and identified by the Global HIV Vaccine Enterprise. Over the 7-year project period the research to be designed and conducted by CHAVI will address: (1) the elucidation of (a) early immunologic and virologic events after HIV-1 infection in humans, and/or (b) immune correlates for protection in animal models; (2) the systematic design and evaluation of immunogens and adjuvants eliciting persistent mucosal and/or systemic immune responses; and (3) the evaluation of vaccine candidates in early phase clinical trials. First year funding will support a CHAVI Director and the awardee institution for (1) the further development and initial implementation of a Scientific Agenda and Strategic Plan for ! all CHAVI activities; (2) the Management and Operations resources to coordinate and manage the entire range of CHAVI activities; (3) research, to be undertaken by the CHAVI Director and investigators in the CHAVI Scientific Leadership Group, focusing on: elucidation of early immunologic and virologic events after HIV infection, and/or elucidation of correlates of immune protection in non-human primate models; as well as initiating the systematic evaluation of vaccine candidates and immunization strategies to enhance mucosal immunity, potency, antigen presentation and immunogenicity; and (4) the development of scientific resources and facilities essential to implement the Scientific Agenda. Expanded funding in the second and subsequent years will support additional research and additional investigators to fully implement the CHAVI Scientific Agenda.